Program 3 – Evaluation, Policy & Ethics

To successfully integrate genomic medicine into the Australian health system we must understand the economic implications, including costs and benefits to patients and their families, the government, society and the health system itself.

Program 3 is building upon the established networks of Australian Genomics' partners for the collection and evaluation of health economic data.  We are analysing and modelling the health and social impact of genomic medicine to inform policy development.

Both retrospective data, to evaluate clinical utility and relative cost per diagnosis, and prospective data collection through the Cancer and Rare Disease Flagships will be applied in the economic analyses.

Developing effective policies will help ensure genomic medicine can be delivered in an equitable, accessible and affordable manner across Australia and that the necessary infrastructure is built to maximise the benefits.

Four projects have been designed to explore these topics.